antipyrine has been researched along with Liver Cirrhosis in 64 studies
Antipyrine: An analgesic and antipyretic that has been given by mouth and as ear drops. Antipyrine is often used in testing the effects of other drugs or diseases on drug-metabolizing enzymes in the liver. (From Martindale, The Extra Pharmacopoeia, 30th ed, p29)
antipyrine : A pyrazolone derivative that is 1,2-dihydropyrazol-3-one substituted with methyl groups at N-1 and C-5 and with a phenyl group at N-2.
Liver Cirrhosis: Liver disease in which the normal microcirculation, the gross vascular anatomy, and the hepatic architecture have been variably destroyed and altered with fibrous septa surrounding regenerated or regenerating parenchymal nodules.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Therefore, we examined its effect of EDA in rat model of liver cirrhosis induced by dimethylnitrosamine (DMN)." | 7.75 | Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine. ( Fukuchi, H; Ichinose, M; Tanaka, H; Ueda, H, 2009) |
| "A significant correlation was found between the alfentanil AUC(infinity(p)) and AUC(infinity)((miosis)) (r = 0." | 7.74 | Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. ( Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007) |
| "Changes in antipyrine clearance and platelet count are more sensitive than conventional tests for indicating fibrotic change in chronic hepatitis C." | 7.72 | Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. ( Byth, K; Coverdale, SA; Crewe, E; Farrell, GC; George, J; Kench, J; Khan, MH; Liddle, C; Lin, R; Samarasinghe, DA, 2003) |
| "In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated." | 7.68 | Fleroxacin pharmacokinetics in patients with liver cirrhosis. ( Blouin, RA; Foster, TS; Hamelin, BA; John, WJ; Smith, DA; Welker, HA, 1992) |
| "To assess the functional activity of a liver with solid metastases from primary colorectal cancer, antipyrine metabolism was studied after the drug was administered orally (18 mg/kg body weight) to 55 healthy volunteers, 62 patients with well-compensated cirrhosis, and 42 patients with small (Class A) or massive (Class B) metastatic liver involvement." | 7.68 | Antipyrine metabolism in patients with liver metastases from colorectal cancer. ( Astone, A; Barone, C; Cassano, A; Castellano, R; Coletta, P; Gambassi, G; Grieco, A; Ragazzoni, E, 1992) |
| "The metabolism of antipyrine to each of its three major metabolites 4-hydroxy-, 3-methylhydroxy- and norantipyrine has previously been demonstrated to be differentially affected in alcoholic cirrhosis." | 7.68 | Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. ( Heidemann, HT; Hoffmann, K; Wensing, G, 1993) |
| "The antipyrine metabolizing capacity was studied in 12 patients with cirrhosis of the liver and 12 with cirrhosis and hepatocellular carcinoma (HCC)." | 7.67 | Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver. ( Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Tarui, S, 1989) |
| "Phenprocoumon was given orally to 9 patients with biopsy proven liver cirrhosis (dose range 0." | 7.67 | The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ( Brundert, E; Büstgens, L; Kitteringham, NR; Mineshita, S; Ohnhaus, EE, 1984) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 7.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| " Therefore, we examined its effect of EDA in rat model of liver cirrhosis induced by dimethylnitrosamine (DMN)." | 3.75 | Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine. ( Fukuchi, H; Ichinose, M; Tanaka, H; Ueda, H, 2009) |
| "A significant correlation was found between the alfentanil AUC(infinity(p)) and AUC(infinity)((miosis)) (r = 0." | 3.74 | Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis. ( Baririan, N; Desager, JP; Horsmans, Y; Starkel, P; Van Obbergh, L; Verbeeck, RK; Wallemacq, P, 2007) |
| "Changes in antipyrine clearance and platelet count are more sensitive than conventional tests for indicating fibrotic change in chronic hepatitis C." | 3.72 | Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression. ( Byth, K; Coverdale, SA; Crewe, E; Farrell, GC; George, J; Kench, J; Khan, MH; Liddle, C; Lin, R; Samarasinghe, DA, 2003) |
| "In this open-label study, the disposition of fleroxacin in liver disease in 12 healthy male volunteers, 6 male cirrhotics without ascites (group A), and 6 male cirrhotics with ascites (group B) was evaluated." | 3.68 | Fleroxacin pharmacokinetics in patients with liver cirrhosis. ( Blouin, RA; Foster, TS; Hamelin, BA; John, WJ; Smith, DA; Welker, HA, 1992) |
| "To assess the functional activity of a liver with solid metastases from primary colorectal cancer, antipyrine metabolism was studied after the drug was administered orally (18 mg/kg body weight) to 55 healthy volunteers, 62 patients with well-compensated cirrhosis, and 42 patients with small (Class A) or massive (Class B) metastatic liver involvement." | 3.68 | Antipyrine metabolism in patients with liver metastases from colorectal cancer. ( Astone, A; Barone, C; Cassano, A; Castellano, R; Coletta, P; Gambassi, G; Grieco, A; Ragazzoni, E, 1992) |
| "The metabolism of antipyrine to each of its three major metabolites 4-hydroxy-, 3-methylhydroxy- and norantipyrine has previously been demonstrated to be differentially affected in alcoholic cirrhosis." | 3.68 | Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis. ( Heidemann, HT; Hoffmann, K; Wensing, G, 1993) |
| "The purpose of this study was to investigate the relationship between two quantitative liver functions, that is, antipyrine blood clearance and aminopyrine blood clearance, in normal subjects and in patients with liver cirrhosis." | 3.68 | A comparison between antipyrine and aminopyrine blood clearances. ( Bandai, Y; Idezuki, Y; Imamura, H; Kawasaki, S; Kokudo, N; Sanjo, K, 1992) |
| "Antipyrine (AP) clearance was determined in 23 cases with liver cirrhosis (LC), 12 with chronic active hepatitis (CAH), 12 with hepatocellular carcinoma (mcHCC), 20 with non-hepatic diseases and 70 healthy controls." | 3.67 | [Evaluation of antipyrine clearance in chronic liver diseases]. ( Wang, JL; Yuan, SY; Zhang, F, 1989) |
| "Phenprocoumon was given orally to 9 patients with biopsy proven liver cirrhosis (dose range 0." | 3.67 | The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon. ( Brundert, E; Büstgens, L; Kitteringham, NR; Mineshita, S; Ohnhaus, EE, 1984) |
| "The antipyrine metabolizing capacity was studied in 12 patients with cirrhosis of the liver and 12 with cirrhosis and hepatocellular carcinoma (HCC)." | 3.67 | Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver. ( Kawata, S; Minami, Y; Miyoshi, S; Noda, S; Tarui, S, 1989) |
| "Blood clearance of antipyrine, indocyanine green, and galactose were measured to evaluate the alterations of effective hepatic blood flow and hepatic intrinsic clearances in chronic liver diseases." | 3.67 | Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases. ( Beppu, T; Hanano, M; Idezuki, Y; Iga, T; Kawasaki, S; Sanjo, K; Sugiura, M; Sugiyama, Y, 1988) |
| "The elimination of pindolol was studied in 32 patients suffering from various liver diseases, mainly acute hepatitis and hepatic cirrhosis." | 3.66 | Elimination of pindolol in liver disease. ( Meier, J; Münch, U; Ohnhaus, EE, 1982) |
| "Patients with acute hepatitis and patients with compensated or decompensated cirrhosis of the liver have a decreased plasma clearance of hexobarbital." | 3.66 | [Drug metabolism in patients with liver disease (author's transl)]. ( Epping, J; Fuchshofen-Röckel, M; Heusler, H; Richter, E; Zilly, W, 1980) |
| " The pharmacokinetic variables for antipyrine were determined using the two concentration time points selected." | 2.73 | Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients. ( Abdel-Kader, R; Botros, S; Hassanein, M; Mahmoud, M; Saleh, S, 2007) |
| "Pharmacokinetic analysis suggests a longer dosage interval may be appropriate in patients with hepatic impairment." | 2.69 | Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers. ( Adams, MH; Ferry, JJ; Garnett, WR; Karnes, HT; Poynor, WJ; Ryan, KK; Sarkar, MA, 1998) |
| " On day 5 there were no statistically significant differences in the Cmax or tmax for ziprasidone between the two groups." | 2.69 | The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function. ( Anderson, KE; Anziano, RJ; Bauer, LA; Carithens, RL; Everson, G; Johnson, A; Lasseter, KC; Smolarek, TA; Turncliff, RZ; Wilner, KD, 2000) |
| " The antipyrine half-life was significantly longer and clearance was significantly lower in patients with cirrhosis." | 2.67 | Pharmacokinetics of encainide in patients with cirrhosis. ( Hoensch, HP; Mönig, H; Ohnhaus, EE; Wensing, G, 1991) |
| " Hepatic pharmacokinetic modelling was performed with a two-phase physiologically-based organ pharmacokinetic model with the vascular space and dispersion evaluated with the MID technique." | 1.38 | Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Weiss, M; Zhang, Q, 2012) |
| " Studies were undertaken using an in situ-perfused rat liver and multiple indicator dilution, and outflow data were analyzed with a physiologically based organ pharmacokinetic model." | 1.37 | Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis. ( Crawford, DH; Fletcher, LM; Li, P; Roberts, MS; Robertson, TA; Thorling, CA; Zhang, Q, 2011) |
| " Terminal half-life (t1/2), was significantly longer in nonascitic patients than in control subjects (32 vs 22 min)." | 1.29 | Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid. ( Ferrara, SD; Frison, G; Mazzo, M; Orlando, R; Padrini, R; Palatini, P; Tedeschi, L; Zordan, R, 1996) |
| " We conclude that the moricizine dose required for arrhythmia patients with hepatic disease should be lower, and perhaps, the dosing frequency should be less than in patients with normal liver function." | 1.29 | The effect of hepatic disease on the disposition of moricizine in humans. ( Davidson, AF; Mayersohn, M; McEntegart, CM; Pieniaszek, HJ; Quon, CY; Sampliner, RE, 1994) |
| "Antipyrine clearance was also evaluated in the same subjects in order to explore the cytoplasmic microsomal efficiency." | 1.29 | The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis. ( Gentile, S; Montella, F; Persico, M; Romano, M; Villano, N, 1994) |
| "Aminopyrine clearance was significantly correlated with liver volume (r = 0." | 1.28 | Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis. ( Bandai, Y; Idezuki, Y; Imamura, H; Kawasaki, S; Sanjo, K, 1992) |
| "Antipyrine clearance was significantly reduced (P less than 0." | 1.28 | Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis. ( Barry, MG; Feely, J; Keeling, PW; Macmathuna, P; Younger, K, 1991) |
| "The present study was designed to compare the pharmacokinetic handling of a single oral dose of nicardipine in normal subjects and in patients with hepatic cirrhosis and to compare the sensitivity of the two groups to its hypotensive effect." | 1.28 | The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine. ( Conway, EL; Drummer, OH; Louis, WJ; McNeil, JJ; Razak, TA; Sewell, RB; Smallwood, RA, 1990) |
| " Propranolol bioavailability correlated with the diameter of the portal vein and was dependent on the size of oesophageal varices and the presence of cavernous transformation of the portal vein." | 1.28 | [Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone]. ( Becker, A; Bołdys, H; Hartleb, M; Kloc, T; Mańczyk, I, 1989) |
| " However, on a pharmacokinetic basis a reduced dosage of midazolam to patients with advanced cirrhosis of the liver is recommended." | 1.28 | Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects. ( Crevoisier, C; Himberg, JJ; Pentikäinen, PJ; Välisalmi, L, 1989) |
| " Thus, the drug-metabolizing capacity in diabetics seems to be markedly reduced, and drug dosage might have to take account of this fact." | 1.27 | [Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus]. ( Dennin, DE; Oltmanns, D; Pentz, R; Siegers, CP, 1984) |
| " Hepatic biotransformation capability before flecainide dosing was assessed by antipyrine challenge." | 1.27 | Pharmacokinetics of flecainide in patients with cirrhosis of the liver. ( Chang, SF; Conard, GJ; McQuinn, RL; Pentikäinen, PJ, 1988) |
| " Thus, on a pharmacokinetic basis the loading dose of mexiletine need not be modified in cirrhotic patients, whereas the maintenance dosage should be reduced to one fourth - one third of the usual dose." | 1.27 | Cirrhosis of the liver markedly impairs the elimination of mexiletine. ( Halinen, MO; Hietakorpi, S; Lampinen, LM; Pentikäinen, PJ, 1986) |
| "Antipyrine clearance was determined in five healthy volunteers, 10 patients with viral hepatitis and 15 patients with cirrhosis of the liver." | 1.26 | Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease. ( Krausz, Y; Levy, M; Zylber-Katz, E, 1980) |
| "The antipyrine test was selected as an in vivo index, since its kinetics indirectly reflect the metabolically active liver mass." | 1.26 | The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus. ( Pelkonen, RO; Salmela, PI; Sotaniemi, EA, 1980) |
| " The average biological half-life after oral administration of 1 g paracetamol was significantly prolonged in patients with hepatic cirrhosis compared to the controls (3." | 1.26 | Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver. ( Andreasen, PB; Hutters, L, 1979) |
| "Antipyrine metabolism was normal or marginally impaired in patients with compensated cirrhosis or acute hepatitis, whereas it was frequently abnormal in those with chronic active hepatitis or advanced alcoholic liver disease." | 1.26 | Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism. ( Cooksley, WG; Farrell, GC; Hart, P; Powell, LW, 1978) |
| "Antipyrine has been used as a model drug to investigate the effects of liver disease on drug metabolism in man." | 1.25 | Determinants of serum antipyrine half-lives in patients with liver disease. ( Branch, RA; Herbert, CM; Read, AE, 1973) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 41 (64.06) | 18.7374 |
| 1990's | 14 (21.88) | 18.2507 |
| 2000's | 7 (10.94) | 29.6817 |
| 2010's | 2 (3.13) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Li, P | 2 |
| Robertson, TA | 2 |
| Thorling, CA | 1 |
| Zhang, Q | 2 |
| Fletcher, LM | 2 |
| Crawford, DH | 2 |
| Roberts, MS | 2 |
| Tanaka, H | 1 |
| Ueda, H | 1 |
| Fukuchi, H | 1 |
| Ichinose, M | 1 |
| Weiss, M | 1 |
| Coverdale, SA | 1 |
| Samarasinghe, DA | 1 |
| Lin, R | 1 |
| Kench, J | 1 |
| Byth, K | 1 |
| Khan, MH | 1 |
| Crewe, E | 1 |
| Liddle, C | 1 |
| George, J | 1 |
| Farrell, GC | 2 |
| NAKOSHI, T | 1 |
| Schneider, AR | 1 |
| Teuber, G | 1 |
| Paul, K | 1 |
| Nikodem, A | 1 |
| Duesterhoeft, M | 1 |
| Caspary, WF | 1 |
| Stein, J | 1 |
| Baririan, N | 1 |
| Van Obbergh, L | 1 |
| Desager, JP | 1 |
| Verbeeck, RK | 1 |
| Wallemacq, P | 1 |
| Starkel, P | 1 |
| Horsmans, Y | 1 |
| Mahmoud, M | 1 |
| Abdel-Kader, R | 1 |
| Hassanein, M | 1 |
| Saleh, S | 1 |
| Botros, S | 1 |
| Prost, O | 1 |
| Ottignon, Y | 1 |
| Rémy-Martin, A | 1 |
| Vuitton, D | 1 |
| Miguet, JP | 1 |
| Adessi, GL | 1 |
| Sotaniemi, EA | 3 |
| Pelkonen, RO | 3 |
| Puukka, M | 1 |
| Vesell, ES | 2 |
| Oltmanns, D | 1 |
| Dennin, DE | 1 |
| Pentz, R | 1 |
| Siegers, CP | 1 |
| Kitteringham, NR | 1 |
| Büstgens, L | 1 |
| Brundert, E | 1 |
| Mineshita, S | 1 |
| Ohnhaus, EE | 4 |
| Okolicsànyi, L | 1 |
| Orlando, R | 2 |
| Lirussi, F | 1 |
| Naccarato, R | 1 |
| Dal Brun, G | 1 |
| Münch, U | 2 |
| Meier, J | 2 |
| Habior, A | 1 |
| Luoma, PV | 1 |
| Arranto, A | 1 |
| Ehnholm, C | 1 |
| Takashi, M | 1 |
| Musha, H | 1 |
| Tsuchiya, S | 1 |
| Gotoh, N | 1 |
| Takayasu, K | 1 |
| Suzuki, N | 1 |
| Kotoda, K | 1 |
| Okuda, K | 1 |
| Escartin, P | 1 |
| Rossi, L | 1 |
| Alvarez Cienfuegos, J | 1 |
| Rodríguez Montes, JA | 1 |
| Garrido, A | 1 |
| Abréu, L | 1 |
| García González, MA | 1 |
| Salmela, PI | 1 |
| Krausz, Y | 1 |
| Zylber-Katz, E | 1 |
| Levy, M | 1 |
| Richter, E | 1 |
| Epping, J | 1 |
| Fuchshofen-Röckel, M | 1 |
| Heusler, H | 1 |
| Zilly, W | 1 |
| Pieniaszek, HJ | 1 |
| Davidson, AF | 1 |
| McEntegart, CM | 1 |
| Quon, CY | 1 |
| Sampliner, RE | 1 |
| Mayersohn, M | 1 |
| Persico, M | 1 |
| Romano, M | 1 |
| Villano, N | 1 |
| Montella, F | 1 |
| Gentile, S | 1 |
| Wensing, G | 2 |
| Hoffmann, K | 1 |
| Heidemann, HT | 1 |
| Ferrara, SD | 1 |
| Tedeschi, L | 1 |
| Frison, G | 1 |
| Mazzo, M | 1 |
| Zordan, R | 1 |
| Padrini, R | 1 |
| Palatini, P | 1 |
| Shrestha, R | 1 |
| McKinley, C | 1 |
| Showalter, R | 1 |
| Wilner, K | 1 |
| Marsano, L | 1 |
| Vivian, B | 1 |
| Everson, GT | 1 |
| Adams, MH | 1 |
| Poynor, WJ | 1 |
| Garnett, WR | 1 |
| Karnes, HT | 1 |
| Ferry, JJ | 1 |
| Ryan, KK | 1 |
| Sarkar, MA | 1 |
| Everson, G | 1 |
| Lasseter, KC | 1 |
| Anderson, KE | 1 |
| Bauer, LA | 1 |
| Carithens, RL | 1 |
| Wilner, KD | 1 |
| Johnson, A | 1 |
| Anziano, RJ | 1 |
| Smolarek, TA | 1 |
| Turncliff, RZ | 1 |
| Trull, A | 1 |
| Hughes, V | 1 |
| Cooper, D | 1 |
| Wilkins, M | 1 |
| Gimson, A | 1 |
| Friend, P | 1 |
| Johnston, A | 1 |
| Sharples, L | 1 |
| Park, G | 1 |
| Andreasen, PB | 3 |
| Hutters, L | 1 |
| Holomán, J | 2 |
| Niederland, TR | 1 |
| Brixová, E | 2 |
| Rikkers, L | 1 |
| Jenko, P | 1 |
| Rudman, D | 1 |
| Freides, D | 1 |
| Cooksley, WG | 1 |
| Hart, P | 1 |
| Powell, LW | 1 |
| Greisen, G | 1 |
| Kawasaki, S | 4 |
| Imamura, H | 2 |
| Kokudo, N | 1 |
| Bandai, Y | 2 |
| Sanjo, K | 4 |
| Idezuki, Y | 4 |
| Grieco, A | 1 |
| Barone, C | 1 |
| Coletta, P | 1 |
| Castellano, R | 1 |
| Ragazzoni, E | 1 |
| Cassano, A | 1 |
| Astone, A | 1 |
| Gambassi, G | 1 |
| Blouin, RA | 1 |
| Hamelin, BA | 1 |
| Smith, DA | 1 |
| Foster, TS | 1 |
| John, WJ | 1 |
| Welker, HA | 1 |
| Mönig, H | 1 |
| Hoensch, HP | 1 |
| Barry, MG | 1 |
| Macmathuna, P | 1 |
| Younger, K | 1 |
| Keeling, PW | 2 |
| Feely, J | 2 |
| Barry, M | 1 |
| Razak, TA | 1 |
| McNeil, JJ | 1 |
| Sewell, RB | 1 |
| Drummer, OH | 1 |
| Smallwood, RA | 2 |
| Conway, EL | 1 |
| Louis, WJ | 1 |
| Noda, S | 2 |
| Kawata, S | 2 |
| Miyoshi, S | 2 |
| Minami, Y | 1 |
| Tarui, S | 1 |
| Wang, JL | 1 |
| Zhang, F | 1 |
| Yuan, SY | 1 |
| Hartleb, M | 2 |
| Kloc, T | 1 |
| Mańczyk, I | 1 |
| Becker, A | 1 |
| Bołdys, H | 2 |
| Pentikäinen, PJ | 3 |
| Välisalmi, L | 1 |
| Himberg, JJ | 1 |
| Crevoisier, C | 1 |
| Morgan, DV | 1 |
| Ito, N | 1 |
| Imai, Y | 1 |
| Saitoh, R | 1 |
| Tamura, S | 1 |
| Inada, M | 1 |
| Inui, Y | 1 |
| Matsuda, Y | 1 |
| Birnie, GG | 1 |
| Fitzsimons, CP | 1 |
| Czarnecki, D | 1 |
| Cooke, A | 1 |
| Scobie, G | 1 |
| Brodie, MJ | 1 |
| Migneco, G | 1 |
| Mascarella, A | 1 |
| Tripi, S | 1 |
| La Cascia, C | 1 |
| Navetta, A | 1 |
| McQuinn, RL | 1 |
| Chang, SF | 1 |
| Conard, GJ | 1 |
| Markiewicz, A | 1 |
| Rudzki, K | 1 |
| Nowak, S | 1 |
| Kacperek, T | 1 |
| Sugiyama, Y | 1 |
| Iga, T | 1 |
| Hanano, M | 1 |
| Beppu, T | 2 |
| Sugiura, M | 1 |
| Villeneuve, JP | 1 |
| Thibeault, MJ | 1 |
| Ampelas, M | 1 |
| Fortunet-Fouin, H | 1 |
| LaMarre, L | 1 |
| Côté, J | 1 |
| Pomier-Layrargues, G | 1 |
| Huet, PM | 1 |
| Narang, AP | 1 |
| Dutta, DV | 1 |
| Khare, AK | 1 |
| Hietakorpi, S | 1 |
| Halinen, MO | 1 |
| Lampinen, LM | 1 |
| Umekita, N | 1 |
| von Mandach, U | 1 |
| Jost, G | 1 |
| Preisig, R | 1 |
| Kupcová, V | 1 |
| Turecký, L | 1 |
| Ulicná, O | 1 |
| Ackermann, E | 1 |
| Renger, F | 1 |
| Dökert, B | 1 |
| Walther, M | 1 |
| Branch, RA | 1 |
| Herbert, CM | 1 |
| Read, AE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Hydromorphone High Resolution Pharmacokinetic-Pharmacodynamic Fingerprint as the Basis for Identifying Sex Differences in Opioid Pharmacokinetics and Pharmacodynamics[NCT01123486] | 0 participants (Actual) | Interventional | 2015-01-31 | Withdrawn (stopped due to PI relocated to new university) | |||
| Reversal of Hepatic Impairment by Achieving Sustained Virologic Response (SVR) With 12 Weeks of Simeprevir(SMV)/Sofosbuvir(SOF)/Ribavirin(RBV) in Patients With Hepatitis C Virus (HCV) Genotype 1 Infection and Early Decompensation of Cirrhosis (MELD 10 or [NCT02455167] | Phase 3 | 9 participants (Actual) | Interventional | 2015-05-31 | Terminated (stopped due to Study stopped due to low accrual and availability of other treatment options) | ||
| Proposal To Develop A Rapid And Cost-Effective Diagnostic Test For Schizophrenia[NCT03781115] | Phase 1 | 24 participants (Anticipated) | Interventional | 2017-11-20 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: 12 Weeks
| Intervention | score on a scale (Mean) |
|---|---|
| HCV Positive Group | 7.25 |
Liver function as assessed via MELD score. The Model For End-Stage Liver Disease (MELD) score assesses the severity of patient liver disease. Possible scores range from 6 to 40, with higher scores indicating more severe liver disease and a worse outcome. (NCT02455167)
Timeframe: Baseline
| Intervention | score on a scale (Mean) |
|---|---|
| HCV Positive Group | 8 |
"Number of participants who cleared Hepatitis C (HCV) after 12 weeks was collected (HCV RNA level was Not Detected." (NCT02455167)
Timeframe: 12 weeks
| Intervention | Participants (Count of Participants) |
|---|---|
| HCV Positive Group | 4 |
1 review available for antipyrine and Liver Cirrhosis
| Article | Year |
|---|---|
Noninvasive assessment in vivo of hepatic drug metabolism in health and disease.
Topics: Adult; Aminopyrine; Animals; Antipyrine; Breath Tests; Humans; Liver; Liver Cirrhosis; Liver Disease | 1984 |
8 trials available for antipyrine and Liver Cirrhosis
| Article | Year |
|---|---|
Patient age is a strong independent predictor of 13C-aminopyrine breath test results: a comparative study with histology, duplex-Doppler and a laboratory index in patients with chronic hepatitis C virus infection.
Topics: Adult; Aged; Aging; Antipyrine; Aspartate Aminotransferases; Breath Tests; Female; Hepatitis C, Chro | 2006 |
Antipyrine clearance in comparison to conventional liver function tests in hepatitis C virus patients.
Topics: Alanine Transaminase; Antipyrine; Aspartate Aminotransferases; Chromatography, High Pressure Liquid; | 2007 |
[Pharmaco-metabolic activity in chronic hepatopathies: influence of treatment with UDPG].
Topics: Adult; Aged; Antipyrine; Chronic Disease; Clinical Trials as Topic; Female; Hepatitis; Humans; Liver | 1980 |
Pharmacokinetics of minoxidil in patients with cirrhosis and healthy volunteers.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Area Under Curve; Biotransformation; Col | 1998 |
The pharmacokinetics of ziprasidone in subjects with normal and impaired hepatic function.
Topics: Adolescent; Adult; Aged; Antipsychotic Agents; Antipyrine; Area Under Curve; Female; Humans; Liver C | 2000 |
Influence of albumin supplementation on tacrolimus and cyclosporine therapy early after liver transplantation.
Topics: Adult; Antipyrine; Creatinine; Cyclosporine; Female; Gelatin; Graft Rejection; Humans; Immunosuppres | 2002 |
Pharmacokinetics of encainide in patients with cirrhosis.
Topics: Adult; Aged; Anilides; Antipyrine; Drug Administration Routes; Encainide; Enzyme Induction; Female; | 1991 |
Comparison of plasma levels of antipyrine, tolbutamide, and warfarin after oral and intravenous administration.
Topics: Administration, Oral; Adult; Antipyrine; Clinical Trials as Topic; Female; Half-Life; Humans; Inject | 1974 |
55 other studies available for antipyrine and Liver Cirrhosis
| Article | Year |
|---|---|
Hepatic pharmacokinetics of cationic drugs in a high-fat emulsion-induced rat model of nonalcoholic steatohepatitis.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antihypertensive Agents; Cations; Cytochrome P-450 | 2011 |
Antifibrotic effect of edaravone in rat liver cirrhosis induced by dimethylnitrosamine.
Topics: Animals; Antipyrine; Bilirubin; Dimethylnitrosamine; Edaravone; Free Radical Scavengers; Histocytoch | 2009 |
Hepatocellular necrosis, fibrosis and microsomal activity determine the hepatic pharmacokinetics of basic drugs in right-heart-failure-induced liver damage.
Topics: Adrenergic Antagonists; Analysis of Variance; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti | 2012 |
Changes in antipyrine clearance and platelet count, but not conventional liver tests, correlate with fibrotic change in chronic hepatitis C: value for predicting fibrotic progression.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Antiviral Agents; Biopsy; Disease | 2003 |
[A NEW THERAPEUTIC METHOD FOR BANTI'S SYNDROME].
Topics: Anemia; Antipyrine; Drug Therapy; Epinephrine; Humans; Hypersplenism; Hypertension, Portal; Idiopath | 1964 |
Alfentanil-induced miosis as a surrogate measure of alfentanil pharmacokinetics in patients with mild and moderate liver cirrhosis.
Topics: Adult; Aged; Alfentanil; Analgesics, Opioid; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Bi | 2007 |
Steroid sulfatase activities in normal and cirrhotic livers and plasma levels of estrone sulfate, estrone and estradiol-17 beta in men.
Topics: Adult; Aged; Antipyrine; Estradiol; Estrogens, Conjugated (USP); Estrone; Humans; Kinetics; Liver Ci | 1984 |
Measurement of hepatic drug-metabolizing enxyme activity in man. Comparison of three different assays.
Topics: Adult; Aged; Antipyrine; Cytochrome P-450 Enzyme System; Enzyme Induction; Female; Glucaric Acid; He | 1980 |
[Antipyrine clearance as a measure of drug metabolism in patients with diabetes mellitus].
Topics: Adolescent; Adult; Aged; Antipyrine; Diabetes Mellitus, Type 1; Fatty Liver; Humans; Liver Cirrhosis | 1984 |
The effect of liver cirrhosis on the pharmacokinetics of phenprocoumon.
Topics: 4-Hydroxycoumarins; Adult; Aged; Antipyrine; Blood Proteins; Half-Life; Humans; Kinetics; Liver Cirr | 1984 |
Elimination of pindolol in liver disease.
Topics: Adolescent; Adult; Aged; Antipyrine; Female; Half-Life; Humans; Kinetics; Liver Cirrhosis; Liver Dis | 1982 |
[Endogenous bile acids in the blood as a functional test in chronic liver diseases. I. Comparison with the antipyrine elimination test].
Topics: Adult; Aged; Antipyrine; Bile Acids and Salts; Chronic Disease; Female; Hepatitis B; Hepatitis, Chro | 1982 |
Plasma high-density lipoproteins and hepatic microsomal enzyme induction. Relation to histological changes in the liver.
Topics: Adult; Aged; Antipyrine; Apoproteins; Biopsy; Cholesterol; Cholesterol, HDL; Cytochrome P-450 Enzyme | 1982 |
[Clinical significance of antipyrine metabolism in patients with various liver diseases (author's transl)].
Topics: Antipyrine; Half-Life; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Liver Function Tests | 1981 |
[Antipyrine and microsomal enzymes clearance].
Topics: Adult; Antipyrine; Cytochrome P-450 Enzyme System; Humans; Liver Cirrhosis; Microsomes, Liver | 1980 |
The evaluation of the drug-metabolizing capacity in patients with diabetes mellitus.
Topics: Antipyrine; Cytochrome P-450 Enzyme System; Diabetes Complications; Diabetes Mellitus; Fatty Liver; | 1980 |
Antipyrine clearance and its correlation to routine liver function tests in patients with liver disease.
Topics: Adult; Aged; Antipyrine; Female; Hepatitis, Viral, Human; Humans; Liver Cirrhosis; Liver Function Te | 1980 |
[Drug metabolism in patients with liver disease (author's transl)].
Topics: Acute Disease; Adult; Antipyrine; Biological Availability; Biotransformation; Cholestasis; Female; H | 1980 |
The effect of hepatic disease on the disposition of moricizine in humans.
Topics: Administration, Oral; Adult; Alanine Transaminase; Antipyrine; Aspartate Aminotransferases; Humans; | 1994 |
The association between rifamycin-SV (R-SV) related hyperbilirubinaemia and antipyrine clearance as a new test of liver function in cirrhosis.
Topics: Adult; Aged; Antipyrine; Bilirubin; Female; Humans; Liver; Liver Cirrhosis; Liver Function Tests; Ma | 1994 |
Antipyrine elimination in patients with alcoholic and non-alcoholic cirrhosis.
Topics: Adult; Antipyrine; Female; Humans; Liver Cirrhosis; Liver Cirrhosis, Alcoholic; Liver Cirrhosis, Bil | 1993 |
Effect of moderate or severe liver dysfunction on the pharmacokinetics of gamma-hydroxybutyric acid.
Topics: Aged; Analysis of Variance; Anti-Inflammatory Agents, Non-Steroidal; Antipyrine; Humans; Hydroxybuty | 1996 |
Quantitative liver function tests define the functional severity of liver disease in early-stage cirrhosis.
Topics: Administration, Oral; Adult; Aged; Antipyrine; Caffeine; Cholic Acid; Cholic Acids; Disease Progress | 1997 |
Paracetamol (acetaminophen) clearance in patients with cirrhosis of the liver.
Topics: Acetaminophen; Adult; Aged; Antipyrine; Female; Half-Life; Humans; Kinetics; Liver Cirrhosis; Liver | 1979 |
[Changes in antipyrine kinetics in liver parenchyma damage (author's transl)].
Topics: Antipyrine; Half-Life; Humans; Kinetics; Liver Cirrhosis | 1979 |
Subclinical hepatic encephalopathy: detection, prevalence, and relationship to nitrogen metabolism.
Topics: Ammonia; Antipyrine; Electroencephalography; Fatty Liver, Alcoholic; Female; Galactose; Hepatic Ence | 1978 |
Drug metabolism in liver disease. Identification of patients with impaired hepatic drug metabolism.
Topics: Acute Disease; Antipyrine; Ascites; Biotransformation; Chemical and Drug Induced Liver Injury; Chole | 1978 |
Two compartment analysis of plasma elimination of phenazone in normals and in patients with cirrhosis of the liver.
Topics: Antipyrine; Humans; Injections, Intravenous; Liver Cirrhosis; Models, Biological; Time Factors | 1976 |
[Comparative study on the elimination of pindolol (visken) and antipyrin in patients with liver diseases].
Topics: Antipyrine; Fatty Liver; Hepatitis; Humans; Liver Cirrhosis; Liver Diseases; Pindolol | 1976 |
A comparison between antipyrine and aminopyrine blood clearances.
Topics: Adult; Aminopyrine; Antipyrine; Female; Humans; Liver Cirrhosis; Liver Function Tests; Male; Metabol | 1992 |
Antipyrine metabolism in patients with liver metastases from colorectal cancer.
Topics: Adult; Aged; Antipyrine; Colorectal Neoplasms; Female; Humans; Liver Cirrhosis; Liver Function Tests | 1992 |
Direct evidence for the intact hepatocyte theory in patients with liver cirrhosis.
Topics: Adult; Aged; Aminopyrine; Antipyrine; Cell Count; Female; Humans; Liver; Liver Cirrhosis; Male; Meta | 1992 |
Fleroxacin pharmacokinetics in patients with liver cirrhosis.
Topics: Administration, Oral; Adult; Aged; Antipyrine; Ascites; Fleroxacin; Humans; Infusions, Intravenous; | 1992 |
Effect of zinc supplementation on oxidative drug metabolism in patients with hepatic cirrhosis.
Topics: Adult; Aged; Antipyrine; Humans; Liver Cirrhosis; Metabolic Clearance Rate; Middle Aged; Oxidation-R | 1991 |
Tissue zinc status and drug elimination in patients with chronic liver disease.
Topics: Antipyrine; Chronic Disease; Female; Humans; Leukocytes; Liver Cirrhosis; Male; Metabolic Clearance | 1990 |
The effect of hepatic cirrhosis on the pharmacokinetics and blood pressure response to nicardipine.
Topics: Adult; Aged; Antipyrine; Biotransformation; Blood Pressure; Female; Half-Life; Humans; Liver; Liver | 1990 |
Antipyrine clearance per unit liver volume in cirrhotics with and without hepatocellular carcinoma indicating a correlation with histological change of the liver.
Topics: Adult; Aged; Antipyrine; Carcinoma, Hepatocellular; Female; Humans; Liver; Liver Cirrhosis; Liver Fu | 1989 |
[Evaluation of antipyrine clearance in chronic liver diseases].
Topics: Adolescent; Adult; Antipyrine; Carcinoma, Hepatocellular; Hepatitis, Chronic; Humans; Liver Cirrhosi | 1989 |
[Usefulness of the evaluation of blood supply and mass of the liver for predicting the rate of pharmacokinetics of lidocaine, propranolol and phenazone].
Topics: Adult; Aged; Antipyrine; Female; Humans; Lidocaine; Liver; Liver Circulation; Liver Cirrhosis; Male; | 1989 |
Pharmacokinetics of midazolam following intravenous and oral administration in patients with chronic liver disease and in healthy subjects.
Topics: Administration, Oral; Adult; Aged; Antipyrine; Half-Life; Humans; Injections, Intravenous; Liver Cir | 1989 |
Hepatic drug clearance in chronic liver disease: can we expect to find a universal, quantitative marker of hepatic function?
Topics: Antipyrine; Biomarkers; Galactose; Humans; Indocyanine Green; Liver Circulation; Liver Cirrhosis; Li | 1989 |
[Alterations of urinary excretion of antipyrine metabolites in patients with cirrhosis of the liver].
Topics: Antipyrine; Carcinoma, Hepatocellular; Edaravone; Female; Humans; Liver Cirrhosis; Liver Neoplasms; | 1987 |
Hepatic metabolic function in patients receiving long-term methotrexate therapy: comparison with topically treated psoriatics, patient controls and cirrhotics.
Topics: Aged; Alkaline Phosphatase; Antipyrine; Female; gamma-Glutamyltransferase; Humans; Indocyanine Green | 1985 |
[Cytolytic episodes during cirrhosis].
Topics: Antipyrine; Anxiety Disorders; Barbiturates; Caffeine; Cholestasis; Drug Therapy, Combination; Femal | 1986 |
Pharmacokinetics of flecainide in patients with cirrhosis of the liver.
Topics: Adult; Aged; Antipyrine; Biotransformation; Female; Flecainide; Humans; Liver; Liver Cirrhosis; Male | 1988 |
[Diurnal variability of hepatic clearance of antipyrine and Tc-99m-HIDA in healthy persons and in those with liver diseases. I].
Topics: Adult; Aged; Antipyrine; Circadian Rhythm; Contrast Media; Fatty Liver; Humans; Imino Acids; Liver; | 1987 |
Hepatic clearances of antipyrine, indocyanine green, and galactose in normal subjects and in patients with chronic liver diseases.
Topics: Adult; Aged; Antipyrine; Chronic Disease; Female; Galactose; Galactosemias; Hepatitis; Humans; Indoc | 1988 |
Drug disposition in patients with HBsAg-positive chronic liver disease.
Topics: Adult; Aminopyrine; Antipyrine; Female; Hepatitis; Hepatitis B Surface Antigens; Hepatitis, Chronic; | 1987 |
Impairment of drug clearance in patients with diabetes mellitus & liver cirrhosis.
Topics: Antipyrine; Diabetes Mellitus; Female; Humans; Kinetics; Liver; Liver Cirrhosis; Male; Metabolic Cle | 1987 |
Cirrhosis of the liver markedly impairs the elimination of mexiletine.
Topics: Adult; Aging; Antipyrine; Blood Proteins; Humans; Injections, Intravenous; Kinetics; Liver Cirrhosis | 1986 |
[Antipyrine plasma clearance in patients with liver cirrhosis].
Topics: Antipyrine; Humans; Liver; Liver Cirrhosis | 1985 |
[Quantification of the drug-metabolizing enzyme system in liver diseases: a comparison between antipyrine saliva clearance and the aminopyrine breath test].
Topics: Adolescent; Adult; Aged; Aminopyrine; Antipyrine; Breath Tests; Carbon Dioxide; Chromatography, High | 1985 |
[Changes in metabolic function of the liver in patients with chronic hepatic diseases].
Topics: Antipyrine; Chronic Disease; Half-Life; Hepatitis; Humans; Liver; Liver Cirrhosis | 1985 |
[Aminophenazone half life in patients with chronic liver parenchyma disorders].
Topics: Aminopyrine; Animals; Antipyrine; Chronic Disease; Fatty Liver; Female; Half-Life; Hepatitis; Humans | 1972 |
Determinants of serum antipyrine half-lives in patients with liver disease.
Topics: Adult; Alkaline Phosphatase; Antipyrine; Aspartate Aminotransferases; Bilirubin; Half-Life; Hepatiti | 1973 |